Mycenax (4726) announced that we have been selected as the finalist of the 2018 CPhI Pharma Awards sponsored by UBM, the world's leading biomedical related exhibition. It will be announced at the CPhI Worldwide and will be held on October 9th in Madrid, Spain.
Mycenax Biotech Inc. has been shortlisted for:
Bioprocessing & Manufacturing
Pharma Company of the Year
We will compete with world-renowned pharmaceutical companies such as Catalent, Merck, and WuXi S TA.
The short-listed technology: MBIConti – Single-use continuous process, is the only one in the world and the first enters the GMP factory to use fully automatic continuous process.
The president of Mycenax Dr. Wen said that the concept of MBIConti is to integrate the improved purification column design in the purification process into a continuous purification platform. In this platform, the purification column becomes smaller, and the purchase amount of the purified resin is reduced each time before the expiration. It can be fully utilized effectively, greatly reducing the procurement cost of purified resin during biopharmaceutical development, and the purification of the column is integrated in the same platform, so that each purification step does not need to be interrupted for collection and storage which means MBIConti reduces process time and reduces the risk of contamination and storage during the producing process. Also, due to the reduction in the procurement of purified resin and the increase in the efficiency of use, the unit cost of future product manufacturing will be greatly reduced, and the reduction of the purification column and the saving of the storage space in the purification step will also shrink the space requirements for the future biopharmaceutical plant construction then greatly reduces capital expenditures.
‘’As biopharmaceuticals, manufacturing is fundamental “said Dr. Wen. Furthermore, Mycenax is taking a new road of innovation, expecting the strength of Taiwan can be noticed. Dr. Wen further explained that Mycenax is expanding its research and development strength, jointly developing with European companies, and actively promoting our services to the US and European markets, and hopes to create a new blue ocean of biopharmaceuticals with this new technological energy.
環球環球生技報導: http://www.gbimonthly.com/2018/09/32108/
經濟日報報導: https://money.udn.com/money/story/5635/3367270?utm_source=Facebook_PicSee
Mycenax (4726) announced that we have been selected as the finalist of the 2018 CPhI Pharma Awards sponsored by UBM, the world's leading biomedical related exhibition. It will be announced at the CPhI Worldwide and will be held on October 9th in Madrid, Spain.
Mycenax Biotech Inc. has been shortlisted for:
Bioprocessing & Manufacturing
Pharma Company of the Year
We will compete with world-renowned pharmaceutical companies such as Catalent, Merck, and WuXi S TA.
The short-listed technology: MBIConti – Single-use continuous process, is the only one in the world and the first enters the GMP factory to use fully automatic continuous process.
The president of Mycenax Dr. Wen said that the concept of MBIConti is to integrate the improved purification column design in the purification process into a continuous purification platform. In this platform, the purification column becomes smaller, and the purchase amount of the purified resin is reduced each time before the expiration. It can be fully utilized effectively, greatly reducing the procurement cost of purified resin during biopharmaceutical development, and the purification of the column is integrated in the same platform, so that each purification step does not need to be interrupted for collection and storage which means MBIConti reduces process time and reduces the risk of contamination and storage during the producing process. Also, due to the reduction in the procurement of purified resin and the increase in the efficiency of use, the unit cost of future product manufacturing will be greatly reduced, and the reduction of the purification column and the saving of the storage space in the purification step will also shrink the space requirements for the future biopharmaceutical plant construction then greatly reduces capital expenditures.
‘’As biopharmaceuticals, manufacturing is fundamental “said Dr. Wen. Furthermore, Mycenax is taking a new road of innovation, expecting the strength of Taiwan can be noticed. Dr. Wen further explained that Mycenax is expanding its research and development strength, jointly developing with European companies, and actively promoting our services to the US and European markets, and hopes to create a new blue ocean of biopharmaceuticals with this new technological energy.
環球環球生技報導: http://www.gbimonthly.com/2018/09/32108/
經濟日報報導: https://money.udn.com/money/story/5635/3367270?utm_source=Facebook_PicSee